FXR | Adooq Bioscience

Cat. No.: A69104

CAS No.: 3067566-36-0

FXR/HSD17B13 modulator 1

FXR/HSD17B13 modulator 1 is a potent modulator targeting the farnesoid X receptor (FXR) and hydroxysteroid dehydrogenase 17 beta 13 (HSD17B13). This compound demonstrates significant biological activity relevant to the study of metabolic dysfunction-associated steatohepatitis (MASH). Its modulation of these targets can provide insights into therapeutic strategies for liver-related metabolic disorders.

In stock View Details

All 2 sizes

Cat. No.: A70457

CAS No.: 570-63-8

3-Epideoxycholic acid

3-Epideoxycholic acid is a modulator of the Farnesoid X receptor (FXR), primarily influencing dendritic cell function. This compound reduces the immunostimulatory capacity of dendritic cells, facilitating the generation of regulatory T cells (Tregs) and exhibiting notable anti-inflammatory effects. Additionally, 3-Epideoxycholic acid promotes the growth of beneficial gut bacteria, specifically Bacteroides, making it relevant for research in immunology and microbiome studies.

In stock View Details

All 4 sizes

Cat. No.: A74876

CAS No.: 3004676-77-8

ZLY28

ZLY28 is a first-in-class dual modulator targeting farnesoid X receptor (FXR) and fatty acid-binding protein 1 (FABP1). This orally active compound exhibits significant potential as an anti-NASH agent, making it a valuable tool for research into nonalcoholic steatohepatitis (NASH) and related metabolic conditions. Its intestinal-restricted activity highlights its specificity, providing an innovative approach to studying lipid metabolism and liver function.

In stock View Details

5 mg

$245.00

10 mg

$405.00

All 5 sizes

Cat. No.: A74905

CAS No.: 3004676-87-0

FXR/CES2 modulator 1

FXR/CES2 modulator 1 is a dual modulator that functions as an FXR agonist and a CES2 inhibitor. This compound demonstrates significant potential in reducing the intestinal toxicity associated with irinotecan administration. Its unique mechanism of action makes it a valuable tool for research aimed at understanding FXR modulation and its implications in gastrointestinal safety during chemotherapy.

In stock View Details

All 3 sizes

Cat. No.: A74907

CAS No.: 2409154-23-8

BAR-2227

BAR-2227 is a modulator that targets the Farnesoid X Receptor (FXR) as an agonist and inhibits the leukemia inhibitory factor receptor (LIFR). This compound plays a significant role in the investigation of liver fibrosis and associated inflammatory responses. Researchers can utilize BAR-2227 to explore its therapeutic potential in liver diseases and further elucidate underlying mechanisms of fibrosis and inflammation.

In stock View Details

All 3 sizes

Cat. No.: A74919

CAS No.: 2982502-32-7

FXR agonist 9

FXR agonist 9 is a selective partial agonist of the farnesoid X receptor (FXR) with an EC50 of 0.09 µM, exhibiting 75.13% maximum efficacy. This compound has demonstrated the ability to improve pathological features associated with metabolic dysfunction and steatohepatitis in mouse models induced by a high-fat diet and carbon tetrachloride. FXR agonist 9 is valuable for research into metabolic disorders and liver diseases.

View Details

Out of stock

All 3 sizes